Effect of serum from postmenopausal women with osteoporosis exhibiting the Kidney‑Yang deficiency pattern on bone formation in an hFOB 1.19 human osteoblastic cell line

Li,Yachan; Liang,Wenna; Li,Xihai; Gao,Bizhen; Gan,Huijuan; Yin,Lianhua; Shen,Jianying; Kang,Jie; Ding,Shanshan; Lin,Xuejuan; Liao,Linghong; Li,Candong

doi:10.3892/etm.2015.2616

Effect of serum from postmenopausal women with osteoporosis exhibiting the Kidney‑Yang deficiency pattern on bone formation in an hFOB 1.19 human osteoblastic cell line

Authors:
- Yachan Li
- Wenna Liang
- Xihai Li
- Bizhen Gao
- Huijuan Gan
- Lianhua Yin
- Jianying Shen
- Jie Kang
- Shanshan Ding
- Xuejuan Lin
- Linghong Liao
- Candong Li
View Affiliations

Affiliations: Research Base of Traditional Chinese Medicine Syndromes, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, The Second Affiliated Hospital, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350004, P.R. China
Published online on: July 3, 2015 https://doi.org/10.3892/etm.2015.2616
Pages: 1089-1095

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the underlying mechanism of the Kidney‑Yang deficiency (KYD) pattern of osteoporosis in postmenopausal women of a certain age range by comparing the effect of serum from postmenopausal women with osteoporosis exhibiting the KYD pattern with that of serum from postmenopausal women without osteoporosis on bone formation in an hFOB 1.19 human osteoblastic cell line. A random selection of 30 female, postmenopausal volunteers aged 60‑70 years, including 15 cases without osteoporosis and 15 cases with the KYD pattern of osteoporosis, were enrolled at the Physical Examination Center of the Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine. Venous blood was extracted and the serum was separated. The hFOB 1.19 cells were treated with 10% KYD pattern‑serum or control serum from postmenopausal women of the same age range without osteoporosis. It was found that the KYD pattern‑serum significantly decreased the cell viability, activity of alkaline phosphatase and number of calcified nodules, as well as downregulated the expression of osteocalcin and osteoprotegerin (OPG) and upregulated that of receptor activator of nuclear factor κB ligand (RANKL) in the hFOB 1.19 cells. In addition, the present results showed that the concentrations of estradiol (E2), OPG and insulin‑like factor‑1 (IGF‑1) in the KYD pattern‑serum were lower than those in the control serum. In combination, these findings suggest that the downregulation of E2, OPG and IGF‑1 in the KYD pattern‑serum inhibits the OPG/RANKL system, leading to a decrease in bone formation in the hFOB 1.19 cells. This indicates that the alterations in E2, OPG and IGF‑1 may account for the susceptibility of certain postmenopausal women to the KYD pattern of osteoporosis.

View Figures

View References

1	Reid IR: Should we prescribe calcium supplements for osteoporosis prevention? J Bone Metab. 21:21–28. 2014. View Article : Google Scholar : PubMed/NCBI
2	Lagari VS and Levis S: Phytoestrogens in the prevention of postmenopausal bone loss. J Clin Densitom. 16:445–449. 2013. View Article : Google Scholar : PubMed/NCBI
3	Liang W, Lin M, Li X, Li C, Gao B, Gan H, Yang Z, Lin X, Liao L and Yang M: Icariin promotes bone formation via the BMP-2/Smad4 signal transduction pathway in the hFOB 1.19 human osteoblastic cell line. Int J Mol Med. 30:889–895. 2012.PubMed/NCBI
4	Hayden RS, Quinn KP, Alonzo CA, Georgakoudi I and Kaplan DL: Quantitative characterization of mineralized silk film remodeling during long-term osteoblast-osteoclast co-culture. Biomaterials. 35:3794–3802. 2014. View Article : Google Scholar : PubMed/NCBI
5	Huang S, Eleniste PP, Wayakanon K, Mandela P, Eipper BA, Mains RE, Allen MR and Bruzzaniti A: The Rho-GEF Kalirin regulates bone mass and the function of osteoblasts and osteoclasts. Bone. 60:235–245. 2014. View Article : Google Scholar : PubMed/NCBI
6	Zhao R: Immune regulation of bone loss by Th17 cells in oestrogen-deficient osteoporosis. Eur J Clin Invest. 43:1195–1202. 2013.PubMed/NCBI
7	Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O and Gabet Y: Regulation of adult bone turnover by sex steroids. J Cell Physiol. 224:305–310. 2010. View Article : Google Scholar : PubMed/NCBI
8	Baek KH, Oh KW, Lee WY, et al: Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: Influences on bone and mineral metabolism. Bone. 39:1352–1360. 2006. View Article : Google Scholar : PubMed/NCBI
9	Cheng M, Wang Q, Fan Y, Liu X, Wang L, Xie R, Ho CC and Sun W: A traditional Chinese herbal preparation, Er-Zhi-Wan, prevent ovariectomy-induced osteoporosis in rats. J Ethnopharmacol. 138:279–285. 2011. View Article : Google Scholar : PubMed/NCBI
10	Xu H and Lawson D: Theories and practice in prevention and treatment principles in relation to Chinese herbal medicine and bone loss. J Tradit Chin Med. 24:88–92. 2004.PubMed/NCBI
11	Damiani G: The Yin and Yang of anti-Darwinian epigenetics and Darwinian genetics. Riv Biol. 100:361–402. 2007.PubMed/NCBI
12	Wang P and Chen Z: Traditional Chinese medicine ZHENG and Omics convergence: A systems approach to post-genomics medicine in a global world. OMICS. 17:451–459. 2013. View Article : Google Scholar : PubMed/NCBI
13	Jiang M, Lu C, Zhang C, Yang J, Tan Y, Lu A and Chan K: Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol. 140:634–642. 2012. View Article : Google Scholar : PubMed/NCBI
14	Lu A, Jiang M, Zhang C and Chan K: An integrative approach of linking traditional Chinese medicine pattern classification and biomedicine diagnosis. J Ethnopharmacol. 141:549–556. 2012. View Article : Google Scholar : PubMed/NCBI
15	Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD and Wang YY: Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol. 1:51–60. 2007. View Article : Google Scholar : PubMed/NCBI
16	Jiang M, Zha Q, Lu C, He Y and Lu A: Association between tongue appearance in Traditional Chinese Medicine and effective response in treatment of rheumatoid arthritis. Complement Ther Med. 19:115–121. 2011. View Article : Google Scholar : PubMed/NCBI
17	Liang W, Li X, Li Y, Li C, Gao B, Gan H, Li S, Shen J, Kang J, Ding S, et al: Tongue coating microbiome regulates the changes in tongue texture and coating in patients with post-menopausal osteoporosis of Gan-shen deficiency syndrome type. Int J Mol Med. 32:1069–1076. 2013.PubMed/NCBI
18	Méndez JP, Rojano-Mejía D, Pedraza J, Coral-Vázquez RM, Soriano R, García-García E, Aguirre-García Mdel C, Coronel A and Canto P: Bone mineral density in postmenopausal Mexican-Mestizo women with normal body mass index, overweight, or obesity. Menopause. 20:568–572. 2013.PubMed/NCBI
19	An S, Li E and Tong X: Study on relationship between estrogen receptor gene polymorphism and syndrome differentiation typing of female postmenopausal osteoporosis in Traditional Chinese medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi. 20:907–910. 2000.(In Chinese). PubMed/NCBI
20	Leung PC and Siu WS: Herbal treatment for osteoporosis: A current review. J Tradit Complement Med. 3:82–87. 2013. View Article : Google Scholar : PubMed/NCBI
21	Gao Z, Lu Y, Halmurat Upur, Jing J and Xu D: Study of osteoporosis treatment principles used historically by ancient physicians in Chinese Medicine. Chin J Integr Med. 19:862–868. 2013. View Article : Google Scholar : PubMed/NCBI
22	Matsumoto Y, Otsuka F, Takano-Narazaki M, Katsuyama T, Nakamura E, Tsukamoto N, Inagaki K, Sada KE and Makino H: Estrogen facilitates osteoblast differentiation by upregulating bone morphogenetic protein-4 signaling. Steroids. 78:513–520. 2013. View Article : Google Scholar : PubMed/NCBI
23	Coelho MJ and Fernandes MH: Human bone cell cultures in biocompatibility testing. Part II: Effect of ascorbic acid, beta-glycerophosphate and dexamethasone on osteoblastic differentiation. Biomaterials. 21:1095–1102. 2000. View Article : Google Scholar : PubMed/NCBI
24	Melville KM, Kelly NH, Khan SA, Schimenti JC, Ross FP, Main RP and van der Meulen MC: Female mice lacking estrogen receptor-alpha in osteoblasts have compromised bone mass and strength. J Bone Miner Res. 29:370–379. 2014. View Article : Google Scholar : PubMed/NCBI
25	Parker BD, Bauer DC, Ensrud KE and Ix JH: Association of osteocalcin and abdominal aortic calcification in older women: The study of osteoporotic fractures. Calcif Tissue Int. 86:185–191. 2010. View Article : Google Scholar : PubMed/NCBI
26	Sapir-Koren R and Livshits G: Is interaction between age-dependent decline in mechanical stimulation and osteocyte-estrogen receptor levels the culprit for postmenopausal-impaired bone formation? Osteoporos Int. 24:1771–1789. 2013. View Article : Google Scholar : PubMed/NCBI
27	Oh SM, Kim HR and Chung KH: Effects of ginkgo biloba on in vitro osteoblast cells and ovariectomized rat osteoclast cells. Arch Pharm Res. 31:216–224. 2008. View Article : Google Scholar : PubMed/NCBI
28	Botella S, Restituto P, Monreal I, Colina I, Calleja A and Varo N: Traditional and novel bone remodeling markers in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 98:E1740–E1748. 2013. View Article : Google Scholar : PubMed/NCBI
29	Stuss M, Rieske P, Cegłowska A, Stêpień-Kłos W, Liberski PP, Brzeziańska E and Sewerynek E: Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab. 98:E1007–E1011. 2013. View Article : Google Scholar : PubMed/NCBI
30	Shoji S, Tabuchi M, Miyazawa K, Yabumoto T, Tanaka M, Kadota M, Maeda H and Goto S: Bisphosphonate inhibits bone turnover in OPG (−/−) mice via a depressive effect on both osteoclasts and osteoblasts. Calcif Tissue Int. 87:181–192. 2010. View Article : Google Scholar : PubMed/NCBI
31	Mazière C, Salle V, Gomila C and Mazière JC: Oxidized low density lipoprotein enhanced RANKL expression in human osteoblast-like cells. Involvement of ERK, NFkappaB and NFAT. Biochim Biophys Acta. 1832:1756–1764. 2013. View Article : Google Scholar : PubMed/NCBI
32	Yasuda H: RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop. 4:207–217. 2013. View Article : Google Scholar : PubMed/NCBI
33	Aubin JE and Bonnelye E: Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 11:905–913. 2000. View Article : Google Scholar : PubMed/NCBI
34	Mozaffari-Khosravi H, Hesabgar HA, Owlia MB, Hadinedoushan H, Barzegar K and Fllahzadeh MH: The effect of garlic tablet on pro-inflammatory cytokines in postmenopausal osteoporotic women: A randomized controlled clinical trial. J Diet Suppl. 9:262–271. 2012. View Article : Google Scholar : PubMed/NCBI
35	Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, et al: Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 110:771–781. 2002. View Article : Google Scholar : PubMed/NCBI
36	Papierska L, Rabijewski M, Kasperlik-Załuska A and Zgliczyński W: Effect of DHEA supplementation on serum IGF-1, osteocalcin and bone mineral density in postmenopausal, glucocorticoid-treated women. Adv Med Sci. 57:51–57. 2012. View Article : Google Scholar : PubMed/NCBI